HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Nov 6, 2024 FY24 Q3 | Feb 19, 2025 FY24 Q4 | Apr 30, 2025 FY25 Q1 | Jul 30, 2025 FY25 Q2 | Oct 29, 2025 FY25 Q3 | Jan 12, 2026 FY25 Q4 | Apr 29, 2026 FY26 Q1 | Jul 29, 2026 FY26 Q2 |
|---|---|---|---|---|---|---|---|---|
| For FY2028 | ||||||||
| Cash flow breakeven | — | — | — | — | New“achieve cash flow breakeven in 2028” | — | — | — |
| Cash flow breakeven target | — | — | — | — | — | New“achieve cash flow breakeven in 2028” | — | — |
| Cashflow breakeven goal | — | — | — | — | — | — | — | New“cashflow breakeven in 2028” |
| Goal of reaching cash-flow breakeven | — | — | — | — | — | — | New“cash-flow breakeven in 2028” | — |
| For FY2026 | ||||||||
| Annual olezarsen peak net sales | — | — | — | — | — | — | New“>$3 billion” | — |
| Total Revenue | — | — | — | — | — | — | New“$875-900 million” | — |
| Cash, cash equivalents and short-term investments | — | — | — | — | — | — | New“>$1.6 billion” | — |
| DAWNZERA full year 2026 product sales | — | — | — | — | — | — | — | New“$110-120 million” |
| DAWNZERA product sales, net | — | — | — | — | — | — | New“$110-120 million” | — |
| Operating expense growth | — | — | — | — | — | — | — | New“low-teens percentage growth year-over-year” |
| Operating loss on a non-GAAP basis | — | — | — | — | — | — | New“$425-475 million” | — |
| TRYNGOLZA full year 2026 product sales | — | — | — | — | — | — | — | New“$100-110 million” |
| TRYNGOLZA product sales, net | — | — | — | — | — | — | New“$100-110 million” | — |
| For FY2025 | ||||||||
| Revenue | — | — | New“$725-750 million” | — | — | — | — | — |
| Total Revenue | — | — | — | New“$825 - 850 million” | Raised“$875-900 million” | — | — | — |
| TRYNGOLZA (olezarsen) annual peak net sales for sHTG | — | — | — | — | — | New“>$2B” | — | — |
| Cash, cash equivalents and short-term investments | — | New“~$1.7 billion” | — | Raised“~$2.0 billion” | Raised“>$2.1 billion” | — | — | — |
| Cash, cash equivalents and short-term investments (year-end expectation) | — | — | New“approximately $1.9 billion” | — | — | — | — | — |
| Financial increase | — | — | New“by more than 20%” | — | — | — | — | — |
| Operating loss on a non-GAAP basis | — | New“<$495 million” | Lowered“<$375 million” | — | — | — | — | — |
| TRYNGOLZA product sales, net | — | — | — | New“$75-80 million” | Raised“$85-95 million” | — | — | — |
| For FY2024 | ||||||||
| Cash | New“$2.2 billion” | — | — | — | — | — | — | — |
| Cash, cash equivalents and short-term investments (year-end projection) | New“$2.2 billion” | — | — | — | — | — | — | — |
| No period stated | ||||||||
| Olezarsen peak net sales | — | — | — | — | — | New“Increasing annual olezarsen peak net sales guidance to >$2 billion from >$1 billion based on strong product profile and positive Phase 3 data” | — | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.